BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Aerial BioPharma Announces Positive Results for ADX-N05 202; a Phase 2b Trial for Narcolepsy


10/1/2013 7:42:01 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Aerial Biopharma Announces Positive Results for ADX-N05 202; A Phase 2b trial for Narcolepsy

MORRISVILLE, NC – (October 1, 2013) – Aerial BioPharma announced today positive results from a Phase 2b clinical study of ADX-N05 in patients with Excessive Daytime Sleepiness associated with narcolepsy. After completing a successful Phase 2a proof-of concept trial in mid-2012, Aerial began the 12-week, 93 patient, Phase 2b study in September 2012 to validate the results in a larger patient population with a longer duration of treatment.

"The preliminary results are remarkable and have the opportunity to have significant impact on the standard of care for patients with narcolepsy" said Dr. Todd Swick, a clinical investigator in the trial and Assistant Clinical Professor of Neurology, University of Texas School of Medicine-Houston .

Given the positive results, the company is now planning a strategic asset sale to accelerate the development of N05. "We are very pleased that we were able to replicate the results from our previous study and are excited about the potential to help patients with this debilitating disease. As a development-stage company, we have turned our focus to finding a strategic partner that will complete the development and maximize commercialization of this important asset." said Dr. Moise Khayrallah, CEO and co-founder of Aerial.

This news comes on the heels of FDA's Patient-Focused Drug Development Meeting on narcolepsy held on September 24, 2013 that highlighted the need for additional research and treatment. Due to patients' clamor, narcolepsy was the first rare disease featured in this series of meetings.

Aerial is the third privately held company from the management team led by Khayrallah, Steve Butts and Gary Bream PhD, all located in the Research Triangle Park, NC area. Since launching Addrenex Pharmaceuticals in 2006, the team has raised and deployed over $30 million for various drug development programs in central nervous systems conditions. Addrenex was acquired by Shionogi Pharma in November 2009 and Neuronex, the team's second company, was acquired by Acorda Therapeutics in 2012. Aerial licensed N05 from SK Biopharmaceuticals.

About Aerial BioPharma

Aerial BioPharma is a privately held biopharmaceutical company focused on developing biologics and small molecules for medical conditions in the central nervous system. Aerial is based in Morrisville, N.C., on the edge of Research Triangle Park. For more information, visit www.aerialbio.com

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES